PRME vs PHAR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PRME · Prime Medicine$3.55 ▼ 7.55%
PHAR · Pharming Group$11.54 ▼ 5.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PRME -6.3%
- PHAR -32.6%
Head to head
| Metric | PRME | PHAR |
|---|---|---|
| Price | $3.55 | $11.54 |
| Change today | ▼ 7.55% | ▼ 5.18% |
| Market cap | $791.62M | $816.78M |
| Return, 3 months | +9.2% | +0.7% |
| Return, year to date | +2.3% | -34.7% |
| Return, 1 year | -2.2% | -29.0% |
| P/E (TTM) | – | 35.0 |
| P/B | 93.4 | 2.8 |
| P/E percentile vs own 5y | 29th | 77th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +243.9% | +20.8% |
| Net profit growth (YoY) | +22.8% | +197.1% |
| Gross margin | – | 85.1% |
| Operating margin | -2,584.2% | 6.7% |
| Net margin | -2,497.6% | 6.3% |
| Return on equity | -207.2% | 8.7% |
| Analyst target vs. price | +131.0% | +238.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 43 | 45 |
| 30-day volatility | 140.8% | 59.3% |
| Max drawdown, 1 year | -42.2% | -57.0% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PHAR is the largest of the group by market value.
- PRME has returned the most over the past year.
- PRME is growing revenue fastest.
- PHAR keeps the most profit per dollar of sales.
- PHAR has been the calmest stock over the last 30 days.